Novartis AG agrees to acquire privately held British biotech Myricx Bio for up to $1.5 billion, expanding its oncology portfolio. Multiple outlets report the purchase is designed to add an experimental cancer-drug approach that targets tumors more directly, with the goal of delivering stronger treatment effects while reducing damage to healthy cells. Bloomberg and other coverage describe Myricx’s technology as focused on delivering more potent therapy to tumor tissue.
The deal includes an upfront payment of about $1.1 billion, with additional consideration of up to $400 million contingent on reaching specified milestones, according to the reports. The Wall Street Journal frames the transaction as a way for Novartis to bolster its oncology capabilities, while other outlets characterize it as part of an ongoing effort across the drug industry to build next-generation cancer pipelines. The acquisition is announced as Myricx Bio remains a privately held company based in the United Kingdom, and details of its pipeline and the specific experimental drug are presented primarily in connection with its tumor-targeted delivery concept.
